Common side effects (usually mild) Injection-related: Injection site redness or irritation Mild pain at injection site Temporary skin induration GH-related: Water retention (usually temporary) Mild headaches (especially initially) Increased hunger (less than GHRP-6) Tingling or numbness (rare, usually at high doses) Sleep-related: Vivid dreams (often reported, not necessarily unpleasant) Temporary sleep disturbance during adjustment Less common side effects At higher doses or prolonged use: Joint stiffness or mild carpal tunnel symptoms Flushing Dizziness Fatigue (paradoxically, sometimes) What Ipamorelin typically doesn't cause Unlike other GHRPs: No significant cortisol elevation No significant prolactin increase No intense hunger spikes No blood sugar disruption Managing side effects For water retention: Usually resolves within 2-4 weeks Reduce sodium intake Stay well-hydrated Consider reducing dose temporarily For headaches: Often occur during first week Ensure proper hydration Start with lower dose and titrate up Usually resolve with continued use For injection site reactions: Rotate injection sites Ensure proper injection technique Allow alcohol to dry before injecting Use fresh needles Contraindications Do not use Ipamorelin if you have: Active cancer or history of cancer Uncontrolled diabetes Severe cardiovascular disease Pregnancy or breastfeeding Known allergy to peptide components Use with caution if you have: Diabetes (monitor blood sugar closely) History of carpal tunnel syndrome Pituitary disorders Any condition affected by growth hormone For comprehensive safety information, see our peptide safety guide
As of 2026, cagrilintide isnt available in the United States, and it isnt part of any FDA-approved medication
Addiction treatment potential: GLP-1 drugs affect brain reward pathways, decreasing reinforcement from alcohol and nicotine
It is available in many forms: creams, lotions, washes, foams, cleansing pads, and gels
Nat Commun 17 , 4477 (2026)
